Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a
donor may be able to replace blood-forming cells that were destroyed by chemotherapy or
radiation therapy. Giving an infusion of the donor's white blood cells (donor lymphocyte
infusion) after the transplant may help destroy any remaining cancer cells
(graft-versus-tumor effect). Sometimes the transplanted cells can make an immune response
against the body's normal cells. Methotrexate, cyclosporine, tacrolimus, or
methylprednisolone may stop this from happening.
PURPOSE: This clinical trial is studying how well a donor stem cell transplant or donor white
blood cell infusions work in treating patients with hematologic cancer.